This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- The Advantage of Antibody Cocktails for Targeted Alpha Therapy Depends on Specific Activity
- Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with 225Ac for {alpha}-Particle Radioimmunotherapy of Cancer
- Sequential Cytarabine and {alpha}-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia
- Anti-CD45 Monoclonal Antibody YAML568: A Promising Radioimmunoconjugate for Targeted Therapy of Acute Leukemia
- Pretargeted {alpha} Emitting Radioimmunotherapy Using 213Bi 1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-Tetraacetic Acid-Biotin
- Pharmacokinetics, Dosimetry, and Toxicity of the Targetable Atomic Generator, 225Ac-HuM195, in Nonhuman Primates
- Targeted alpha particle immunotherapy for myeloid leukemia
- Tumor Therapy with Targeted Atomic Nanogenerators
- High-Level Production of {alpha}-Particle-Emitting 211At and Preparation of 211At-Labeled Antibodies for Clinical Use
- Response of LNCaP Spheroids after Treatment with an {{alpha}}-Particle Emitter (213Bi)-labeled Anti-Prostate-specific Membrane Antigen Antibody (J591)
- An {{alpha}}-Particle Emitting Antibody ([213Bi]J591) for Radioimmunotherapy of Prostate Cancer